Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26141052 | 0.88 | CYP3A4 (0.41) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL12263157 | 0.88 | CYP3A4 (0.47) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL1702135 | 0.83 | HMGCR (0.36) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL1106488 | 0.75 | NOS3 (0.36) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL12553815 | 0.74 | IDH1 (0.37) | IDH1 | |
| SCHEMBL20780144 | 0.72 | IDH1 (0.36) | IDH1 | |
| SCHEMBL21212206 | 0.72 | ADRB1 (0.44) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL30318104 | 0.72 | ADRB1 (0.37) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL20773042 | 0.71 | CDK2 (0.41) | CYP3A4TSHRCYP2C19IDH1 | |
| SCHEMBL22764043 | 0.70 | CYP3A4 (0.33) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | CYP3A4 4200/4885CYP2D6 4473/4885TSHR 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.